Glioblastoma multiforme (GBM), a fatal malignant brain tumor, represents a challenge in terms of developing new treatments. Solutions have been proposed in connection with anti-tumor immune responses, generally T cell strategies, including techniques targeting growth factors, particularly IGF-I, the primary cancer growth factor, and its signal transduction pathways. The objective of this review is to assess the immunogene mechanism targeting IGF-I, which constitutes the basis of the described cancer gene therapy for GBM, stemming from brain neoplastic development studies. The GBM gene therapy, based on new strategies of anti-gene IGF-I techniques, including antisense or triple helix, has been combined with phytochemicals (phenolics) and nanotechnologies (theranostic nanoparticles). The three approaches have modulated IGF-I expression together, inducing common signal transduction pathways: IGF-I-R, TK/PI3K/AKT/TLR/MAPK & JAK/STAT. These signals have transformed in vitro neoplastic glioma cells into immunogenic cells. These immunogenic cells, which express MHC-1 and B7, produce a strong T CD8 anti-tumour immune response after in vivo injection. The combined strategy of anti-IGF-I/phytochemical/nanotechnology vaccines has shown promising clinical results, with patient survival of up to two and three years in some cases. The obtained results are discussed in parallel with other immunotherapies and antitumour vaccine studies that involve the immunogenicity mechanism.
The brain malignant tumor Glioblastoma multiforme (GBM) has a median survival of 14–16 months using current treatments; thus, understanding the pathology of GBM is crucial for proposing new therapies and increasing overall survival outcomes. Therefore, this study aimed to analyze different elements, particularly growth factors and the related signal transduction pathways, which play a role in brain neoplastic development, from stem cells to established solid brain tumors, and the application of current immunology techniques, molecular biology, and nanotechnology. Targeting growth factors, especially insulin-like growth factor-1 (IGF-I) (the principal neoplastic development factor) using anti-gene technologies—antisense and triple helix—has previously been shown to produce an immune anti-tumor response (CD8, CD28) through the TK/PI3K/AKT pathway. This immune response was increased using phytochemicals (phenolics), especially nanoparticles (theranostic nanoparticles), by modulating IGF-I through common pathways (IGF-I-R and TK/PI3K/AKT/TLR/MAPK and JAK/STAT). This review demonstrates how studies on central nervous system neoplastic development progressively led to establishing clinical cancer gene therapies, increasing GBM survival by 20–24 months. The presented studies compare the results of cancer gene therapy with other current immunotherapies. Moreover, this research chapter briefly describes the investigations of nanotechnology related to neurotumorigenesis and GBM therapies. The presented studies relate to nanotechnology and compare the results of cancer gene therapy with other current immunotherapies.